1 / 13

PHL 424 Antimicrobials

Antiviral Agents. Antiviral Agents, Overview. Viruses are obligate intracellular parasites that consist of either double- or single-stranded DNA or RNA enclosed in a protein coat called a capsidSome viruses also possess a lipid envelope that, like the capsid, may contain antigenic glycoproteinsMos

tal
Télécharger la présentation

PHL 424 Antimicrobials

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    1. PHL 424 Antimicrobials

    2. Antiviral Agents

    3. Antiviral Agents, Overview

    4. Antiviral Agents, Overview

    5. Acyclovir, Overview

    6. Acyclovir is converted to the monophosphate (MP) derivative by viral thymidine kinase, then to acyclovir-DP and acyclovir-TP by cellular enzymes Uninfected cells convert very little or no drug to the phosphorylated derivatives Acyclovir, MOA

    8. Acyclovir, Resistance and Adverse Effects

    9. Zidovudine, Overview

    10. Zidovudine, Clinical Uses, Resistance and Adverse Effects Efficacy has also been demonstrated in the treatment of HIV-associated dementia and thrombocytopenia In pregnancy, a regimen of oral zidovudine beginning between 14 and 34 weeks of gestation (100 mg five times a day), i.v. zidovudine during labor (2 mg/kg over 1 hour, then 1 mg/kg/h by continuous infusion), and zidovudine syrup to the neonate from birth through 6 weeks of age (2 mg/kg every 6 hours) has been shown to reduce the rate of vertical (mother-to-newborn) transmission of HIV by up to 23% Efficacy has also been demonstrated in the treatment of HIV-associated dementia and thrombocytopenia In pregnancy, a regimen of oral zidovudine beginning between 14 and 34 weeks of gestation (100 mg five times a day), i.v. zidovudine during labor (2 mg/kg over 1 hour, then 1 mg/kg/h by continuous infusion), and zidovudine syrup to the neonate from birth through 6 weeks of age (2 mg/kg every 6 hours) has been shown to reduce the rate of vertical (mother-to-newborn) transmission of HIV by up to 23%

    11. Interferon Alfa, Overview

    12. Interferon Alfa, Mechanism of Action and Indications

    14. Interferon Alfa, Adverse Effects

More Related